453 SIGNATURE RESISTANCE MUTATIONS TO DIRECTLY ACTING ANTIVIRAL AGENTS OCCUR AT LOW PREVALENCE IN TREATMENT NAIVE SUBJECTS WITH RECENTLY ACQUIRED HEPATITIS C INFECTION

2011 ◽  
Vol 54 ◽  
pp. S184-S185 ◽  
Author(s):  
S. Gaudieri ◽  
T. Applegate ◽  
M. Tshochner ◽  
A. Plauzolles ◽  
K. Pfafferott ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Agents ◽  
Resistance Mutations ◽  
Hepatitis C Infection ◽  
Treatment Naïve ◽  
Low Prevalence

scholarly journals Low prevalence of hepatitis C infection among HIV-infected individuals in Slovenia: a nationwide study, 1985–2013

2014 ◽  
Vol 14 (S4) ◽  
Author(s):  
Katja Seme ◽  
Mateja Škamperle ◽  
Maja M Lunar ◽  
Polona Maver Vodičar ◽  
Janez Tomažič ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hepatitis C Infection ◽  
Nationwide Study ◽  
Low Prevalence

scholarly journals Hepatitis C virus vaccine development: old challenges and new opportunities

2015 ◽  
Vol 2 (3) ◽  
pp. 285-295 ◽  
Author(s):  
Dapeng Li ◽  
Zhong Huang ◽  
Jin Zhong
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Vaccine Development ◽  
Rna Virus ◽  
Antiviral Agents ◽  
Resistance Mutations ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Hepatitis C virus (HCV), an enveloped positive-sense single-stranded RNA virus, can cause chronic and end-stage liver diseases. Approximately 185 million people worldwide are infected with HCV. Tremendous progress has been achieved in the therapeutics of chronic hepatitis C thanks to the development of direct-acting antiviral agents (DAAs), but the worldwide use of these highly effective DAAs is limited due to their high treatment cost. In addition, drug-resistance mutations remain a potential problem as DAAs are becoming a standard therapy for chronic hepatitis C. Unfortunately, no vaccine is available for preventing new HCV infection. Therefore, HCV still imposes a big threat to human public health, and the worldwide eradication of HCV is critically dependent on an effective HCV vaccine. In this review, we summarize recent progresses on HCV vaccine development and present our views on the rationale and strategy to develop an effective HCV vaccine.

scholarly journals Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies

2020 ◽  
Vol Volume 13 ◽  
pp. 4235-4248
Author(s):  
Mohamed M Adel El-Sokkary ◽  
Lizaveta Gotina ◽  
Mohammad M. Al-Sanea ◽  
Ae Nim Pae ◽  
Rehab Mohammed Elbargisy
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Molecular Characterization ◽  
In Silico ◽  
Antiviral Agents ◽  
In Silico Prediction ◽  
Resistance Mutations
Sign in / Sign up

Export Citation Format

Share Document